



## **Beat Mullhaupt**

### **Kontakt**

Beat Mullhaupt

## Publikationen (43)

Radu P, Becchetti C, Schropp J, Schmid P, Künzler-Heule P, Mertens J, Moradpour D, Mullhaupt B, Semela D, Negro F, Heim M, Clerc O, Roelens M, Keiser O, Berzigotti A, Swiss Hepatitis C Cohort Study. Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection. *Cancers (Basel)* 2024; 16

Pop O, Geng A, Flint E, Singanayagam A, Ercan C, Possamai L, Patel V, Künzler-Heule P, Meier M, Soysal S, Hruz P, Kollmar O, Tatham K, Ward J, Mullhaupt B, Weber A, Wendon J, Niess J, Heim M, Semela D, Weston C, Antoniadou C, Terracciano L, Triantafyllou E, Brenig R, Bernsmeier C. AXL expression on homeostatic resident liver macrophages is reduced in cirrhosis following GAS6 production by hepatic stellate cells. *Cell Mol Gastroenterol Hepatol* 2023

Bihl F, Semmo N, Semela D, Scheidegger C, Razavi H, Negro F, Mullhaupt B, Lavanchy D, Dufour J, Castro Batánjer E, Bruggmann P, Blach S. HCV disease burden and population segments in Switzerland. *Liver Int* 2021

Vieira Barbosa J, Moradpour D, Weber A, Lenggenhager D, Sempoux C, Mathurin P, Louvet A, Artru F, Gouttenoire J, Neuweiler J, Cathomas G, Montani M, Semela D, Filipowicz Sinnreich M, Brunner F, Mullhaupt B, Fraga M. Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. *Swiss Med Wkly* 2021; 151:w20502.

Mullhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. *Swiss Med Wkly* 2021; 151:w20399.

Semmo N, Mullhaupt B, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Semela D. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. *PloS one* 2020; 15:e0241267.

Roelens M, Keiser O, Negro F, Junker C, Semela D, Clerc O, Mullhaupt B, Schmid P, Semmo N, Cerny A, Moradpour D, Bertisch B, Swiss Hepatitis C Cohort Study. All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). *Open Forum Infect Dis* 2020; 7:ofaa308.

Dietz J, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C, Buggisch P, Matschenz K, Spengler U, Mullhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K, Berger A, European HCV Resistance Study Group. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. *Clin Gastroenterol Hepatol* 2019

About F, Casanova J, Theodorou I, Sultanik P, Poynard T, Pol S, Bochud P, Cobat A, Abel L, Swiss Hepatitis C Cohort Study Group, Semmo N, Semela D, Bibert S, Jouanguy E, Nalpas B, Lorenzo L, Rattina V, Zarhrate M, Hanein S, Munteanu M, Mullhaupt B, French ANRS HC EP 26 Genoscan Study Group. Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. *Front Genet* 2019; 10:1024.

Brezzi M, Keiser O, Negro F, Semela D, Mullhaupt B, Semmo N, Terziroli Beretta-Piccoli B, Moradpour D, Roelens M, Bertisch B, Swiss Hepatitis C Cohort Study. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. *PloS one* 2019; 14:e0218706.

Bertisch B, Keiser O, Moradpour D, Zehnder C, Marinucci F, Roelens M, Moriggia A, Clerc O, Giudici F, Schmid P, Künzler-Heule P, Ottiger C, Mullhaupt B, Negro F, Brezzi M, Swiss Hepatitis C Cohort Study. Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?. *Clin Infect Dis* 2019

Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Mullhaupt B, Negro F, Semela D. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. *Swiss Med Wkly* 2019; 149:w14694.

Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Robbins Scott S, Semela D, Negro F. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. *PLoS one* 2018; 13:e0209374.

Geier A, Mullhaupt B, Bischoff-Ferrari H, Saleh L, Marques Maggio E, Jahn D, Bantel H, Tschopp O, Seifert B, Tay F, Semela D, Stirnimann G, Eichinger M, Dufour J. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. *Scand J Gastroenterol* 2018;1-7.

Schreiber P, Mullhaupt B, Schiesser M, Boggian K, Reiner C, Vrugt B, Kröger A, Fagagnini S, Schmid A, Günthard H. MRI and PET-CT Failed to Differentiate Between Hepatic Malignancy and Brucelloma. *Open Forum Infect Dis* 2018; 5:ofy052.

Bachofner J, Mertens J, Terziroli Beretta-Piccoli B, Mullhaupt B, Magenta L, Semela D, Fehr J, Moncsek A, Seifert B, Braun D, Baserga A, Künzler-Heule P, Kröger A, Bergamin I, Valli P, The Swiss Hepatitis C Cohort Study. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. *Swiss Med Wkly* 2018; 148:w14560.

Bruggmann P, Stoeckle M, Semela D, Schmid P, Razavi H, Rauch A, Mullhaupt B, Lavanchy D, Kouyos R, Fehr J, Deltenre P, Blach S, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. *Swiss Med Wkly* 2017; 147:w14543.

Fraga M, Sahli R, Greub G, Telenti A, Aubert V, Terziroli Beretta-Piccoli B, Stickel F, Semela D, Ripellino P, Mullhaupt B, Brunner F, Bihl F, Moulin H, Doerig C, Moradpour D. Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. *Liver Int* 2017

Lenggenhager D, Moradpour D, Sempoux C, Mullhaupt B, Rubbia-Brandt L, Terracciano L, Sahli R, Fraga M, Aepli P, Hürliemann S, Neuweiler J, Semela D, Kreutzer S, Honcharova-Biletska H, Bawohl M, Malehmir M, Gouttenoire J, Weber A. Visualization of hepatitis E virus RNA and proteins in the human liver. *J Hepatol* 2017; 67:471-479.

Gauthiez E, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P, Malinverni R, Heim M, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. *Liver Int* 2017; 37:1431-1445.

De Gottardi A, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek F, Valla D, Garcia-Pagan J, Navascués C, Mullhaupt B, Puente A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver Int* 2016

Bachofner J, Mullhaupt B, Terziroli Beretta-Piccoli B, Magenta L, Semela D, Fehr J, Moncsek A, Seifert B, Braun D, Baserga A, Künzler-Heule P, Bergamin I, Kröger A, Valli P, Mertens J. DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI. *Liver Int* 2016

Gordic S, Puijpe G, Krauss B, Klotz E, Desbiolles L, Lesurtel M, Mullhaupt B, Pfammatter T, Alkadhi H. Correlation between Dual-Energy and Perfusion CT in Patients with Hepatocellular Carcinoma. *Radiology* 2016; 280:78-87.

Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Mullhaupt B, Razavi H, Semela D. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. *Swiss Med Wkly* 2015; 145:w14221.

Schmid P, Weber R, Opravil M, Vernazza P, Mullhaupt B, Jochum W, Rauch A, Huber M, Bregenzer A, Swiss HIV Cohort Study. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. *PloS one* 2015; 10:e0138838.

Wang H, Pichulik T, Mullhaupt B, Semela D, Dufour J, Bochud P, Bowie A, Kalinke U, Berg T, Weber A, Wiese M, Löffler M, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery S, Filomena A, Wolz O, Schneiderhan-Marra N, East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. *Hepatology* 2015; 62:1375–87.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Corrigendum: reduced IFN $\lambda$ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2015; 6:7280.

Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. *PloS one* 2015; 10:e0125214.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Reduced IFN $\lambda$ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2014; 5:5699.

Morard I, Negro F, Bochud P, Pascarella S, Semela D, Mullhaupt B, Moradpour D, Malinverni R, Heim M, Gorgievski M, De Gottardi A, Cerny A, Mangia A, Calmy A, Clément S, Swiss Hepatitis C Cohort Study Group. Clinical significance of the CCR5delta32 allele in hepatitis C. *PloS one* 2014; 9:e106424.

Lange C, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud P, Hiroshima Liver Study Group, Mullhaupt B, Malinverni R, Heim M, Miki D, Ochi H, Nischalke H, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour J, Gorgievski-Hrisoho M, Swiss Hepatitis C Cohort Study Group. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. *PloS one* 2013; 8:e64053.

Lange C, Bochud P, Kutalik Z, Moradpour D, Semela D, Negro F, Mullhaupt B, Malinverni R, Kaiser L, Heim M, Cerny A, Cellerai C, Dufour J, Bibert S, Swiss Hepatitis C Cohort Study Group. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. *J Hepatol* 2013; 59:504–9.

Rau M, Geier A, Mullhaupt B, Semela D, Moradpour D, Dufour J, Dill M, Schmitt J, Weisskopf M, Becker P, Manser C, Russmann S, Stickele F, Swiss Hepatitis C Cohort Study Group (SCCS). Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. *J Hepatol* 2012; 58:669–75.

Kuske L, Dufour J, Cerny A, Malinverni R, Heim M, Malé P, Moradpour D, Semela D, Negro F, Mullhaupt B, Mensen A, Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. *Swiss Med Wkly* 2012; 142:w13651.

Patin E, Stewart G, Booth D, George J, Casanova J, Bréchet C, Rice C, Talal A, Jacobson I, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud P, Abel L, Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium, Suppiah V, Martinetti G, Hirsch H, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Mullhaupt B, Semela D, Dufour J, Heim M, Moradpour D, Cerny A, Malinverni R, French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012; 143:1244–52.e1–12.

Gonvers J, Troillet N, Negro F, Monnat M, Malinverni R, Dutoit V, Dufour F, Chuard C, Chave J, Cerny A, Borovicka J, Bernasconi E, Genné D, Mullhaupt B, Cavassini M, Heim M, Oneta C. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. *Swiss Med Wkly* 2010; 140:w13055.

Rauch A, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann J, Berg T, Bergmann S, Negro F, Telenti A, Bochud P, Swiss Hepatitis C Cohort Study, Heim M, Günthard H, Furrer H, Kuznetsov Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour J, Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010; 138:1338-45, 1345.e1-7.

Bochud P, Negro F, Francioli P, Malinverni R, Cerny A, Moradpour D, Heim M, Borovicka J, Mullhaupt B, Dufour J, Bochud M, Overbeck K, Cai T, Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *Journal of hepatology* 2009; 51:655-66.

Riener M, Jochum W, Moch H, Fritzsche F, Wild P, Neuhaus P, Bahra M, Clavien P, Mullhaupt B, Hellerbrand C, Probst-Hensch N, Samaras P, Pestalozzi B, Breitenstein S, Soll C, Liewen H, Stenner F, Kristiansen G. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. *Hepatology (Baltimore, Md.)* 2009; 49:1602-9.

Johansen P, Bot A, Speck R, Gerlach T, Mullhaupt B, Senti G, Lang K, Manolova V, Smith K, Der-Sarkissian A, Qiu Z, Rettig L, Storni T, Kündig T. Antigen kinetics determines immune reactivity. *Proceedings of the National Academy of Sciences of the United States of America* 2008; 105:5189-94.

Wildi S, Gubler C, Hany T, Petrowsky H, Clavien P, Jochum W, Gerlach T, Fried M, Mullhaupt B. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. *Journal of clinical ultrasound : JCU* 2008; 36:20-6.

Mullhaupt B, Dimitroulis D, Gerlach T, Clavien P. Hot topics in liver transplantation: organ allocation--extended criteria donor--living donor liver transplantation. *Journal of hepatology* 2008; 48 Suppl 1:S58-67.

Helbling B, Renner E, Meyer-Wyss B, Esteban A, Mullhaupt B, Dinges S, Wilhelmi M, Gonvers J, Borovicka J, Cerny A, Knöpfli M, Stamenic I, Jochum W, Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. *Journal of viral hepatitis* 2006; 13:762-9.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)